



## **Tarsometatarsal Arthrodesis - Single Service**

*Clinical Guidelines for Medical Necessity Review*

**Version:** 2  
**Effective Date:** September 20, 2024

# Important Notices

## Notices & Disclaimers:

**GUIDELINES SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION MAKING OF END USERS.**

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice.

©2024 Cohere Health, Inc. All Rights Reserved.

---

## Other Notices:

HCPCS® and CPT® copyright 2024 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

---

## Guideline Information:

**Specialty Area:** Diseases & Disorders of the Musculoskeletal System  
**Guideline Name:** Tarsometatarsal Arthrodesis (Single Service)

**Literature review current through:** 9/20/2024

**Document last updated:** 9/20/2024

**Type:**  Adult (18+ yo) |  Pediatric (0-17 yo)

## **Table of Contents**

<b>Important Notices</b>	<b>2</b>
Table of Contents	3
<b>Medical Necessity Criteria</b>	<b>4</b>
<b>Service: Tarsometatarsal Arthrodesis</b>	<b>4</b>
General Guidelines	4
Medical Necessity Criteria	4
Indications	4
Non-Indications	5
Level of Care Criteria	5
Procedure Codes (CPT/HCPCS)	5
<b>Medical Evidence</b>	<b>6</b>
<b>References</b>	<b>8</b>
<b>Clinical Guideline Revision History/Information</b>	<b>9</b>

# Medical Necessity Criteria

## **Service: Tarsometatarsal Arthrodesis**

### General Guidelines

- **Units, Frequency, & Duration:** None.
- **Criteria for Subsequent Requests:** None.
- **Recommended Clinical Approach:** Tarsometatarsal (TMT) joint arthrodesis may be used to treat more severe and advanced hallux valgus deformities, especially those with first TMT joint instability or arthritis.<sup>1-3</sup>
- **Exclusions:** None.

### Medical Necessity Criteria

#### Indications

- **Tarsometatarsal arthrodesis** is considered appropriate if **ALL** of the following are **TRUE**:
- ◆ The patient has **ANY** of the following positive findings:
    - Bunion deformity with persistent pain and difficulty walking; **OR**
    - Hypermobility of the first TMT joint documented; **OR**
    - Painful TMT joint with tenderness on exam; **AND**
  - ◆ Failure of conservative management for greater than 3 months, including **ALL** of the following<sup>2-3</sup>:
    - Oral steroids, anti-inflammatory medications, or analgesics; **AND**
    - Shoe modifications; **AND**
    - Protective cushions/pads; **AND**
    - Orthotics; **AND**
    - **ANY** of the following:
      - Corticosteroid injection if medically appropriate; **OR**
      - Corticosteroid injection is contraindicated; **AND**
  - ◆ Radiographic confirmation (must be weight-bearing radiographs of the foot) of **ANY** of the following:
    - Intermetatarsal (IM) angle greater than 16 degrees<sup>3</sup>; **OR**

- Advanced osteoarthritis of the tarsometatarsal (TMT) joint (e.g., joint space narrowing, osteophyte formation, subchondral cysts).

### Non-Indications

→ **Tarsometatarsal arthrodesis** is not considered appropriate if **ANY** of the following is **TRUE**:

- ◆ The patient has not reached skeletal maturity; **OR**
- ◆ ABI less than 0.7<sup>4</sup>; **OR**
- ◆ The presence of active, untreated infection at the surgical site (may be necessary for a DM ulcer correction).

### Level of Care Criteria

Outpatient

### Procedure Codes (CPT/HCPCS)

CPT/HCPCS Code	Code Description
28297	Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with first metatarsal and medial cuneiform joint arthrodesis, any method
28735	Arthrodesis, midtarsal or tarsometatarsal, multiple or transverse; with osteotomy (eg, flatfoot correction)
28740	Arthrodesis, midtarsal or tarsometatarsal, single joint

## Medical Evidence

Schwartz et al. (2024) conducted a two-part, randomized, double-blind, active-controlled trial. The study examined the efficacy, safety, and how liposomal bupivacaine (LB) works in the body when given through ultrasound-guided sciatic nerve block in the popliteal fossa during bunionectomy surgery. When administered through a sciatic nerve block in the popliteal fossa following a bunionectomy, LB 133 mg exhibited superior and enduring pain management compared to BUPI. The results are clinically significant as they were accompanied by simultaneous decreases in pain levels and opioid usage for up to 4 days post-surgery, with a notably higher proportion of participants abstaining from opioids. (ClinicalTrials.gov Identifier: NCT05157841).<sup>5</sup>

Ilfeld et al. (2021) performed a randomized controlled trial (RCT) to determine the impact of percutaneous peripheral nerve stimulation on postoperative pain levels and usage of opioids. Study participants included patients undergoing foot/ankle, knee, or shoulder surgeries. Each patient received percutaneous peripheral nerve stimulation preoperatively, followed by a single injection of long-acting local anesthetic along the same nerve. Postoperatively, patients were randomized into groups receiving active or sham stimulation for 14 days. The primary outcome measures were opioid consumption and pain scores within the first 7 postoperative days. Results showed that participants receiving active stimulation had significantly lower opioid consumption and pain scores compared to those receiving sham treatment. The authors concluded that percutaneous peripheral nerve stimulation effectively reduced pain and opioid requirements after ambulatory orthopedic surgery without systemic side effects.<sup>6</sup>

Stødle et al. (2020) conducted an RCT to evaluate primary arthrodesis of the first tarsometatarsal (TMT) joint in comparison to temporary bridge plating for managing unstable Lisfranc injuries. The study compared primary arthrodesis (PA) and temporary bridge plate (BP) treatments for Lisfranc injuries, 48 patients were followed for 2 years. PA involved fusing the medial 3 TMT joints, while BP involved placing a plate over the first TMT joint and fusing the second and third TMT joints. The main outcome measured was the American Orthopaedic Foot & Ankle Society (AOFAS) midfoot scale, with

secondary measures including SF-36, VAS pain scores, and radiographic assessments. Results showed no significant difference in AOFAS scores between groups, but better alignment of the first metatarsal was noted in the BP group. Overall, favorable outcomes were noted for both treatments.<sup>7</sup>

## References

1. Coetzee JC, Wickum D. The Lapidus procedure: A prospective cohort outcome study. *Foot Ankle Int.* 2004 Aug;25(8):526-31. doi: 10.1177/107110070402500803. PMID: 15363372.
2. Thomas JL, Blitch EL, et al. Diagnosis and treatment of forefoot disorders. Section I: Digital deformities. *J Foot Ankle Surg.* 2009 Mar-Apr;48(2):230-8. doi: 10.1053/j.jfas.2008.12.003. PMID: 19232978.
3. Shi, GG, Whalen JL, Turner NS, et al. Operative approach to adult hallux valgus deformity: Principles and techniques. *J Foot Ankle Surg.* 2009 Mar-Apr;48(2):230-8. doi: 10.1053/j.jfas.2008.12.003. PMID: 19232978.
4. McClary KN, Massey P. Ankle brachial index. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 Jan 16. PMID: 31334946.
5. Schwartz G, Gadsden JC, Gonzales J, et al. A phase 3 active-controlled trial of liposomal bupivacaine via sciatic nerve block in the popliteal fossa after bunionectomy. *J Clin Anesth.* 2024 Jun:94:111402. doi: 10.1016/j.jclinane.2024.111402. PMID: 38340677.
6. Ilfeld BM, Plunkett A, Vijjeswarapu AM, et al. Percutaneous peripheral nerve stimulation (neuromodulation) for postoperative pain: A randomized, sham-controlled pilot study. *Anesthesiology.* 2021 Jul 1;135(1):95-110. doi: 10.1097/ALN.0000000000003776. PMID: 33856424; PMCID: PMC8249357.
7. Stødle AH, Hvaal KH, Brøgger HM, et al. Temporary bridge plating vs primary arthrodesis of the first tarsometatarsal joint in Lisfranc injuries: Randomized controlled trial. *Foot Ankle Int.* 2020 Aug;41(8):901-910. doi: 10.1177/1071100720925815. PMID: 32501109; PMCID: PMC7406968.

# Clinical Guideline Revision History/Information

Original Date: April 19, 2024		
Review History		
Version 2	9/20/2024	Updated language regarding conservative treatment. Added non-indication for "ABI less than 0.7".